($millions, except per-share data )__ Three Months Ended

June 30

2009__ 2008

Net Sales__ $261.0__ $279.3

Gross Profit__ 78.7__ 83.6

Reported Operating Profit__ 28.6__ 42.6

Adjusted Operating Profit (1)__ 29.0__ 37.4

Reported Diluted EPS__ $0.57__ $0.82

Adjusted Diluted EPS(1)__ $0.58__ $0.73

(1) Reported second quarter results in each year included restructuring

charges and, in 2008, income from a contract settlement. See the

corresponding notes under "Supplemental Information and Notes to Non-GAAP

Financial Measures" in the tables following the text of this release.

Consolidated sales were 6.6% lower in the quarter when compared to the prior year period, primarily due to adverse effects of foreign currency translation, which reduced reported sales by $20.2 million. Excluding currency translation effects, consolidated sales were 0.7% higher than in the prior year quarter.

Consolidated gross profit margin was 30.2% in the quarter, compared to 29.9% in the second quarter of 2008. The overall margin increase reflected the net positive effects of higher year-over- year sales prices and a more profitable sales mix, which together exceeded increases in production costs, including labor, utilities and other indirect costs. Raw material costs had a mixed effect on margins, as Pharmaceutical Systems segment material costs remained above prior year levels despite recent declines in relevant commodity prices, while those commodity price declines reduced both revenues and costs in the Tech Group segment. Gross profit was $78.7 million in the current quarter, reflecting $6.1 million in adverse foreign currency translation and the positive effect of the margin improvement. Excluding the impact of currency translation, gross profit grew 1.4% compared to the prior-year quarter.

Adjusted consolidated operating profit reflects a $2.6 million pre-tax increase in U.S. pension expense, which is the result of pension fund investment losses incurred in 2008, as well as $1.0 million of incremental information technology spending and depreciation, and $0.7 million of higher stock-based compensation costs. Those effects on SG&A costs were mitigated by $2.4 million of favorable effects of foreign currency translation on foreign subsidiaries' costs. Foreign currency translation and higher pension expense combined to reduce earnings by approximately $0.13 per diluted share compared to the second quarter of 2008.

Executive Commentary

"Our second quarter performance exceeded our prior guidance, with help from a weaker dollar and some accelerated orders from our North American customers in particular," said Donald E. Morel Jr., Ph.D., the Company's Chairman and Chief Executive Officer. "Even without those positive benefits, we would have exceeded our earlier expectations. We continue to remain cautiously optimistic on the outlook for the remainder of the year given the current global economic environment and uncertainty surrounding the impact of the ongoing healthcare reform debate in the U.S.

"We are increasing our full-year revenue estimate by about 1% and now expect 2009 adjusted EPS to be between $2.10 and $2.20. While the Tech Group segment had a strong first half, demand for contract manufacturing services is expected to soften in the second half for a number of consumer and healthcare products. We currently believe that the lower Tech demand will be more than offset by improvements in the Pharmaceutical Systems segment, where our backlog remains strong. We continue to expect further positive effects from lower production costs as a result of our lean-manufacturing efforts and lower raw material costs. We have thoroughly reviewed our 2009 plans and intend to hold capital spending to between $110 million and $120 million. Our original plan was to spend $140 million this year.

"For our three to five year planning horizon, we foresee no long- term, fundamental change to our growth opportunities. West will continue investing in those opportunities in order to generate sustainable and profitable growth for all of our stakeholders."

Pharmaceutical Systems Segment

Pharmaceutical Systems segment sales were $197.8 million in the current quarter, compared to $212.6 million in the second quarter of 2008. Unfavorable foreign currency translation reduced comparable quarterly sales by $18.2 million, or 8.6%. Excluding the effects of currency translation, sales grew by $3.4 million. Sales improvements included a substantial increase in sales of components for prefillable syringes and lining materials used for vial, syringe and cartridge seals, notably for insulin products. Other product categories that improved were drug reconstitution systems, and seals for vials and cartridges. The impact of those gains was muted by lower sales of components for lyophilized drug products and disposable medical devices. Geographically, and excluding the effects of currency translation, overall sales in the Company's largest markets in North America and Europe grew marginally, while sales in the Company's smaller Asian business grew by $2.3 million.

Gross profit in the quarter was $66.9 million, compared to $73.2 million in the 2008 quarter, and gross margin was 33.8%, 0.6 percentage points lower than in the prior-year period. The decline in gross profit was attributed largely to a $5.5 million adverse effect of currency translation. The balance of the change in gross profit was due to higher overall production costs, including labor, material and indirect costs, which combined to outpace increases in selling prices. Raw material costs remained higher during the quarter compared to the same period last year despite declines in global commodity prices from the peak levels reached in late 2008. Certain of the Company's purchasing agreements delay the pass- through of commodity price changes. Lower commodity prices are expected to have a positive effect on margins and gross profit during the second half of 2009.

Pharmaceutical Systems SG&A costs declined slightly during the second quarter compared to the 2008 period, but were higher as a percentage of sales, as a result of comparatively lower sales. Currency translation lowered reported costs by $2.3 million. A $2.0 million cost increase included additional spending on information systems, including depreciation and other project-related costs, and outside services, including commissions and acquisition-related legal services. Research spending was substantially unchanged from the prior-year quarter. Resulting operating profit was $34.2 million, compared to $40.3 million in the second quarter of 2008, with currency translation accounting for $3.2 million of the $6.1 million change.

Tech Group Segment

Tech Group segment sales were $66.8 million in the second quarter, down from $69.6 million in the prior year period. Currency translation accounted for a $2.0 million decline, and a $2.9 million reduction was due to lower plastic resin prices, which are passed through to customers. Partially offsetting those declines were improved contract manufacturing revenue for healthcare products, including injection pens and components, auto-injectors and medical filters, while sales slowed for consumer product-related molding and assembly.

Gross profit was $11.8 million in the quarter, a 13.5% increase over the second quarter of 2008, and gross profit margin improved 2.8 percentage points, to 17.7%. Improvements were associated with a stronger product mix, including continued strength in healthcare- related devices and associated production efficiencies in the affected facilities. SG&A costs increased by $0.7 million, primarily the result of higher employee medical benefit costs. Operating profit increased from $4.7 million in the prior year period to $6.1 million, reflecting the stronger gross profit margin.

Corporate and Other

Consistent with reported results for the first quarter of 2009, $4.1 million of U.S. pension expense recorded in the second quarter was $2.6 million higher than in the prior-year period as a result of the effects of substantial investment losses incurred by the U.S. pension plan assets during 2008. Similar quarterly increases are expected over the remainder of 2009.

Stock-based compensation expense increased by $0.7 million compared to the prior year quarter due to the effects of changes in the Company's share price on affected plans. The Company's share price increased during the current quarter and declined during the 2008 period. Other corporate general and administrative costs were a combined $0.4 million higher.

Net interest expense was substantially unchanged from the prior- year period. The Company's reported tax expense reflects an expected 2009 annual tax rate of 24.4%, excluding the tax effects of "Restructuring and Other Items", described below, and any discrete tax costs or benefits. The comparable expected annual tax rate in the 2008 period was 26.8%. The primary reasons for the rate reduction are reinstatement of the U.S. credit for research activities and a more tax-efficient distribution of international earnings.

Restructuring and Other Items

West announced an operational restructuring plan for the Tech Group segment in 2007 and concluded that plan during the second quarter of 2009. Pre-tax charges of $0.4 million were incurred in the current quarter, bringing the total 2009 plan-related pre-tax costs to $1.1 million. Reported 2008 second-quarter results included $1.4 million of comparable costs.

2008 second quarter results included $6.6 million of pre-tax income under a contract settlement agreement with Nektar Therapeutics. That agreement provided for the reimbursement of the Company's costs of maintaining and converting the former Exubera(R) device production facility following the termination of production of that product. The settlement has no impact on results in the current quarter.

Financial Guidance

The Company revised its 2009 guidance.